ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
The ACR/ARHP Annual Meeting in San Diego offered new details from studies of new and existing therapies across a range of rheumatic diseases, from rheumatoid arthritis to rare diseases. Scrip shares notes here from interviews with Lilly, Ironwood, Corbus and Samumed.
You may also be interested in...
The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations.
Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.